CY1122483T1 - Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης - Google Patents

Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης

Info

Publication number
CY1122483T1
CY1122483T1 CY20201100028T CY201100028T CY1122483T1 CY 1122483 T1 CY1122483 T1 CY 1122483T1 CY 20201100028 T CY20201100028 T CY 20201100028T CY 201100028 T CY201100028 T CY 201100028T CY 1122483 T1 CY1122483 T1 CY 1122483T1
Authority
CY
Cyprus
Prior art keywords
lyophydried
precautions
melphalan flufenamide
pharmaceutical preparations
lyophilized pharmaceutical
Prior art date
Application number
CY20201100028T
Other languages
English (en)
Inventor
Jack Spira
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of CY1122483T1 publication Critical patent/CY1122483T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Η παρούσα εφεύρεση αναφέρεται σε λυοφιλοποιημένες φαρμακευτικές παρασκευές που περιλαμβάνουν μελφαλάνη φλουφεναμίδη, ή φαρμακευτικώς αποδεκτά άλατα αυτής, και σακχαρόζη. Επιπλέον ανεξάρτητες αξιώσεις αναφέρονται σε μεθόδους για την παρασκευή τους, σε συνθέσεις που περιέχουν τις λυοφιλοποιημένες φαρμακευτικές παρασκευές και στη χρήση τους στη θεραπεία του καρκίνου.
CY20201100028T 2012-10-26 2020-01-13 Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης CY1122483T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719184P 2012-10-26 2012-10-26
SE1251211 2012-10-26
PCT/SE2013/051246 WO2014065751A1 (en) 2012-10-26 2013-10-24 Lyophilized preparations of melphalan flufenamide

Publications (1)

Publication Number Publication Date
CY1122483T1 true CY1122483T1 (el) 2021-01-27

Family

ID=50544986

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100028T CY1122483T1 (el) 2012-10-26 2020-01-13 Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης

Country Status (18)

Country Link
US (2) US10285946B2 (el)
EP (2) EP2928463B1 (el)
JP (1) JP6284945B2 (el)
KR (1) KR102205592B1 (el)
CN (2) CN104994847B (el)
AU (1) AU2013335359B2 (el)
BR (1) BR112015009280B1 (el)
CA (1) CA2889753C (el)
CY (1) CY1122483T1 (el)
HK (1) HK1216501A1 (el)
IL (1) IL238398B (el)
MX (1) MX365205B (el)
NZ (1) NZ708016A (el)
PL (1) PL2928463T3 (el)
RS (1) RS60068B1 (el)
RU (1) RU2643762C2 (el)
SI (1) SI2928463T1 (el)
WO (1) WO2014065751A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128462A1 (en) 2011-04-28 2014-05-08 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
US10285946B2 (en) 2012-10-26 2019-05-14 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
DK3866931T3 (da) 2018-10-18 2023-04-24 Oncopeptides Ab Forbindelser indeholdende deuterium
US20220193019A1 (en) 2019-04-03 2022-06-23 Oncopeptides Ab Treatment of al amyloidosis with melflufen
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
SE0002202D0 (sv) * 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
US6992207B2 (en) * 2000-06-13 2006-01-31 Oncopeptides Ab Melphalan derivatives and their use as cancer chemotherapeutic drugs
US20040247628A1 (en) * 2001-10-24 2004-12-09 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
ES2339298T3 (es) * 2006-07-07 2010-05-18 Gilead Sciences, Inc. Compuesto de piridazina novedoso y uso del mismo.
JP2010510327A (ja) * 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ，インコーポレーテッド エンドキシフェンの方法および組成物
CN101584669B (zh) * 2009-06-19 2010-12-29 江苏奥赛康药业有限公司 美法仑冻干粉针剂
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
LT2696848T (lt) 2011-04-15 2020-09-10 Janssen Pharmaceutica N.V. Liofilizuotos vaisto nanosuspensijos
US20140128462A1 (en) * 2011-04-28 2014-05-08 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
US10285946B2 (en) 2012-10-26 2019-05-14 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide

Also Published As

Publication number Publication date
RS60068B1 (sr) 2020-05-29
EP2928463A4 (en) 2016-08-31
US20160271065A1 (en) 2016-09-22
CN108685860A (zh) 2018-10-23
RU2015118581A (ru) 2016-12-20
JP2015535243A (ja) 2015-12-10
KR102205592B1 (ko) 2021-01-20
IL238398B (en) 2018-03-29
BR112015009280A2 (pt) 2017-07-04
WO2014065751A1 (en) 2014-05-01
EP2928463B1 (en) 2019-11-20
HK1216501A1 (zh) 2016-11-18
US10285947B2 (en) 2019-05-14
EP2928463A1 (en) 2015-10-14
US20150335578A1 (en) 2015-11-26
NZ708016A (en) 2018-02-23
CN104994847B (zh) 2018-08-10
BR112015009280B1 (pt) 2022-05-31
MX2015005217A (es) 2015-07-14
CA2889753C (en) 2021-03-02
CN104994847A (zh) 2015-10-21
IL238398A0 (en) 2015-06-30
EP3628318A1 (en) 2020-04-01
MX365205B (es) 2019-05-27
AU2013335359B2 (en) 2016-07-21
JP6284945B2 (ja) 2018-02-28
PL2928463T3 (pl) 2020-06-01
KR20150070375A (ko) 2015-06-24
AU2013335359A1 (en) 2015-05-14
CN108685860B (zh) 2022-04-05
SI2928463T1 (sl) 2020-03-31
CA2889753A1 (en) 2014-05-01
RU2643762C2 (ru) 2018-02-05
US10285946B2 (en) 2019-05-14

Similar Documents

Publication Publication Date Title
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1121736T1 (el) Άλατα aramchol
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar